Amgen Inc.

Alexander David Frenkel

Jay Patrick Powers

Frank Kayser

Daqing Sun

Rajiv Sharma

Zhulun Wang

Christopher Neil Farthing

Sarah Lively

Jinqian Liu

Sarah Elizabeth Lively

Stephen J Shuttleworth

Andrew Smith

Craig Tomooka

Martin J Harrison

David Craig McGowan

Xiaotian Zhu

David John Kopecky

Erin F DiMauro

John Laird Buchanan

XianYun Jiao

William H Buckner

Simon A Burkitt

Teresa L Marshall

Paul Faulder

The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

Furanopyrimidines

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.

Benzimidazole derivatives

Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.

Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity

Growing community of inventors

Buxton, United Kingdom

Alexander David Frenkel